Advertising of medicines and dietary supplements: how to avoid AMCU fines
Advertising of medicines and dietary supplements: how to avoid AMCU fines
An analysis of the decisions of the Antimonopoly Committee of Ukraine (AMCU) for 2020–2025 shows that the most common violation in the advertising of medicines and dietary supplements is the dissemination of misleading information.
The maximum fine for such a violation may reach up to 5% of the company’s revenue from product sales for the last reporting year preceding the year in which the fine is imposed.
In light of the COVID-19 pandemic and quarantine restrictions, during 2020–2021 the AMCU investigated unfair practices in the advertising of medicines. Following the study, the AMCU published a report and advisory recommendations for participants in the pharmaceutical market, which remain relevant today and should be considered when preparing advertising materials.
Read more in the article by EVERLEGAL lawyers for LIGA ZAKON at the link.
In focus:
- AMCU practice regarding the advertising of medicines and dietary supplements in 2020–2025;
- typical violations that may mislead consumers;
- risks associated with claims about the speed of action, market leadership, quality and price of medicines;
- requirements for substantiating therapeutic and preventive claims in advertising;
- common violations in the advertising of dietary supplements and the practice of imposing fines;
- recommendations for businesses on reviewing advertising materials and reducing the risks of AMCU sanctions.
Our experts:
Yaroslav Medvediev, Counsel at EVERLEGAL
Vladyslav Shulkin, Associate at EVERLEGAL
More about EVERLEGAL's expertise at the link:
For enquiries and consultations, please complete the short form on our website.
